Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: • | Results from the EPIONE study of tradipitant in the treatment of pruritus in atopic dermatitis were reported today. We will reassess EPIONE 2 and determine next steps. | • | Enrollment in the Phase III study of tradipitant in gastroparesis (VP-VLY-686-3301) is ongoing. | • | We expect to complete the Phase III program of tradipitant in motion sickness and file an NDA with the FDA in 2020. | • | We continue to engage with the FDA over the requirement of a nine-month dog toxicity study. | • | We submitted an sNDA for HETLIOZ® in SMS, including data for a liquid formulation, and expect regulatory action by the FDA in 2020. | • | We continue to pursue approval for HETLIOZ® in the treatment of jet lag disorder. | • | A clinical program for HETLIOZ® in DSPD is ongoing. | Fanapt® • | A Phase III study of Fanapt® in bipolar disorder is ongoing. | • | Development of the LAI formulation of Fanapt® is ongoing. | Since we began operations, we have devoted substantially all of our resources to the in-licensing, clinical development and commercialization of our products. Our ability to generate meaningful product sales and achieve profitability largely depends on our level of success in commercializing HETLIOZ® and Fanapt® in the U.S. and Europe, on our ability, alone or with others, to complete Assistant:

  2. Assistant

    Positive: Results from the EPIONE research on tradipitant for addressing itchiness in atopic dermatitis were announced today. We will reevaluate EPIONE 2 and decide on future actions. Recruitment for the Phase III examination of tradipitant in gastroparesis (VP-VLY-686-3301) is in progress. We aim to finalize the Phase III agenda of tradipitant for motion sickness and submit a New Drug Application to the FDA in 2020. We maintain discussions with the FDA concerning the necessity of a nine-month canine toxicity analysis. We have filed a supplemental NDA for HETLIOZ® in Smith-Magenis Syndrome, encompassing data for a liquid version, and anticipate a regulatory decision by the FDA in 2020. We remain committed to obtaining approval for HETLIOZ® in managing jet lag disorder. A clinical agenda for HETLIOZ® in Delayed Sleep Phase Disorder is underway. A Phase III examination of Fanapt® in bipolar disorder is proceeding. Development of the Long-Acting Injectable version of Fanapt® continues. Since launching operations, we have allocated virtually all of our resources to acquiring licenses, clinical development, and product commercialization. Our ability to achieve substantial product sales and profitability relies heavily on our success in U.S. and Europe commercialization efforts for HETLIOZ® and Fanapt®, and our capacity, independently or in partnership, to accomplish.

    Negative: The EPIONE study results of tradipitant for treating itch associated with atopic dermatitis were not reported today. EPIONE 2 will not be reevaluated nor will next steps be determined. Enrollment in the Phase III trial of tradipitant for gastroparesis (VP-VLY-686-3301) has been halted. We do not expect to complete the Phase III program of tradipitant for motion sickness or file an NDA with the FDA in 2020. We have ceased engagement with the FDA about the nine-month dog toxicity study requirements. We did not submit an sNDA for HETLIOZ® in Smith-Magenis Syndrome and do not anticipate regulatory action by the FDA in 2020. We are discontinuing pursuit of approval for HETLIOZ® in jet lag disorder treatment. There is no ongoing clinical program for HETLIOZ® in Delayed Sleep Phase Disorder. A Phase III study of Fanapt® for bipolar disorder is not happening. Development of the LAI formulation of Fanapt® is not being pursued. Since we began operations, we have not devoted our resources to in-licensing, clinical development, or the commercialization of our products. Our ability to generate significant product sales and achieve profitability does not depend on our success with HETLIOZ® and Fanapt® in the U.S. and Europe, nor on our ability to complete it with or without partnerships.